Vertigo-Vomex

Quick links to important sections

Vertigo-Vomex

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vertigo-Vomex

What is Vertigo-Vomex?

Vertigo-Vomex is a medicinal product used primarily for the management of symptoms associated with various forms of dizziness and motion sickness. It contains the active ingredient dimenhydrinate, which belongs to a class of medications known as antihistamines. Specifically, dimenhydrinate is a first-generation H1 receptor antagonist.

Mechanism of Action

The active substance in Vertigo-Vomex works by influencing the vestibular system and the vomiting center located in the brain. Dimenhydrinate blocks the action of histamine at the H1 receptors, which helps to suppress the signals that trigger nausea, vomiting, and sensations of vertigo. Additionally, it possesses anticholinergic properties that further contribute to its effect on the balance organs in the inner ear.

Primary Uses

Vertigo-Vomex is utilized to address a range of conditions related to equilibrium and gastrointestinal distress caused by motion. These include:

  • Vertigo: Assisting in the reduction of dizziness and the sensation of spinning or swaying.
  • Nausea and Vomiting: Managing gastric upset linked to disturbances in the inner ear or balance.
  • Motion Sickness: Providing relief from symptoms experienced during travel by car, boat, or airplane.

Composition

While the primary active component is dimenhydrinate, the formulation may also contain auxiliary substances that assist in the delivery and stability of the medication. Depending on the specific presentation, these may include binders, fillers, or coating agents necessary for the tablet or capsule structure.

Regulatory References

  1. Dimenhydrinate: MedlinePlus Drug Information

What side effects are possible with Vertigo-Vomex?

Possible side effects and safety information

The safety profile of Vertigo-Vomex, primarily based on its Dimenhydrinate component, is characterized by effects categorized within specific System-Organ Classes (SOCs), as detailed in official regulatory documents.

Commonly Documented Adverse Reactions

The most frequent adverse reactions listed in regulatory labeling are related to Central Nervous System (CNS) depression and anticholinergic effects. These include drowsiness (somnolence), typically classified as common, and frequently reported anticholinergic effects such as dry mouth and constipation.


System-Organ Class Effects and Serious Reactions

Adverse effects are documented across several systems. Nervous System Disorders may include headache and dizziness. Eye Disorders may involve blurred vision, and Renal and Urinary Disorders may include difficulty passing urine (urinary retention).

Serious adverse reactions, though less frequent, are officially listed. These include the documented potential for severe allergic reactions or paradoxical CNS effects such as agitation, hallucinations, or convulsions, particularly noted in children. The label also addresses the potential for acute worsening of conditions like angle-closure glaucoma.


Population-Specific Safety Considerations

Official prescribing information includes specific safety considerations for patient groups. Older adults may be more susceptible to CNS effects, including increased drowsiness, confusion, and the risk of urinary retention. Conversely, the pediatric population may be more likely to experience paradoxical excitement or hyperactivity.

Furthermore, the regulatory label notes that the sedative effect may be more pronounced at the beginning of treatment. The drug also carries a constraint against use with co-administered medications that can cause ear damage, as it may mask symptoms of ototoxicity.

Overdose and Emergency Response

Vertigo-Vomex Overdose and When to Seek Help

The official regulatory profile for Vertigo-Vomex overdose emphasizes the acute effects of the antihistamine component (Dimenhydrinate). Overdose manifestations may range from severe CNS depression, including drowsiness progressing to coma and respiratory depression, to CNS excitation, which can involve agitation, hallucinations, and convulsions. Acute toxicity also presents with signs of anticholinergic syndrome, such as tachycardia, mydriasis (dilated pupils), and urinary retention.

Severe overdosage is associated with life-threatening consequences, including ventricular dysrhythmias, severe hypotension, and potential cardiorespiratory collapse. Due to the risk of such severe or life-threatening outcomes, immediate medical attention must be sought for any suspected overdose. Pediatric patients are documented as being particularly susceptible to the effects of CNS excitation.

Emergency treatment is defined as symptomatic and supportive, and regulatory documents describe procedures like gastric decontamination and close ECG monitoring of cardiac function. No specific antidote is known. Furthermore, chronic high-dose exposure to the vitamin components is separately documented to carry risks for hepatotoxicity (Nicotinic Acid) and sensory neuropathy (Pyridoxine HCl).

Therapeutic Uses of Vertigo-Vomex

Quick Facts

  • May help prevent or manage nausea associated with motion sickness.
  • May help prevent or manage vomiting associated with motion sickness.
  • May help prevent or manage dizziness associated with motion sickness.
  • May be used to manage symptoms related to certain inner ear disturbances, such as vertigo.

Vertigo-Vomex (dimenhydrinate) is an established antiemetic option used to address symptoms related to motion sickness. Its primary therapeutic domains include supporting the prevention and management of nausea, vomiting, and dizziness that may occur during travel or movement. This medicine is also used to help manage the symptoms of inner ear issues, including vertigo and disturbances such as Meniere's disease.

The medication is used to control symptoms, which may support improved comfort and a reduction in the incidence of vomiting when symptoms are expected or active. This medicine may also be used in some cases for the prevention or management of nausea and vomiting in the period following certain procedures.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Vertigo-Vomex?

This section defines population eligibility based on official regulatory labeling for dimenhydrinate combination products.

Contraindicated Populations (Must Not Use)

Classification Population/Condition
Absolute Contraindication Known hypersensitivity to dimenhydrinate, diphenhydramine, or other ingredients.
Absolute Contraindication Patients with Narrow-angle Glaucoma.
Absolute Contraindication Children under 2 years of age (unless directed by a physician).
Absolute Contraindication Concurrent use of a Monoamine Oxidase Inhibitor (MAOI) within 14 days.
Absolute Contraindication Neonates and Premature Infants (especially for injectable forms).
Condition Restriction Severe Hepatic Impairment or Severe Renal Impairment.

Age-Related Eligibility

Adults and children 12 years of age and older are typically approved for standard use. For children between 2 and 12 years, use is approved but subject to specific weight/age-based guidelines. Older adults (65 years and older) are advised caution as the drug may not be as safe or effective as alternatives.

Conditional Use (Caution Required)

The medicine should be used with caution in patients with conditions that may be aggravated by anticholinergic effects, including Prostatic Hypertrophy leading to urine retention, certain Cardiac Arrhythmias, and chronic lung conditions like Asthma or COPD. Caution is also required for patients with a history of Seizure Disorders (Epilepsy).

Pregnancy and Lactation Status

The drug is classified as FDA Pregnancy Category B and its use during gestation is recommended only if clearly needed. Since dimenhydrinate is excreted into breast milk, official labeling advises that a decision must be made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vertigo-Vomex (Dimenhydrinate) has documented interactions stemming from its properties as an antihistamine and a central nervous system (CNS) depressant. The primary concerns involve additive effects with other substances.

Category Interaction Mechanism and Effect Clinical Classification
CNS Depressants Additive sedation; increased drowsiness and impairment of mental or physical abilities. Use with Caution/Avoid
Anticholinergic Agents Potentiation of side effects such as dry mouth, blurred vision, or confusion. Use with Caution/Avoid
Monoamine Oxidase Inhibitors (MAOIs) Potentiation of anticholinergic and CNS effects, leading to potentially life-threatening risks. Contraindicated
QT-Prolonging Drugs Increased risk of serious cardiac dysrhythmias (e.g., Torsades de Pointes). Avoid Combination
Ototoxic Agents Dimenhydrinate can mask early signs of ear damage (ototoxicity) caused by certain antibiotics (e.g., Aminoglycosides). Use with Caution/Monitor
Alcohol Enhanced sedative effects and impaired ability to drive or operate machinery. Avoid Use

It is also noted that Dimenhydrinate and its metabolite, Diphenhydramine, inhibit the CYP2D6 enzyme system, which may affect the metabolism and increase the blood concentrations of other drugs that are substrates of this enzyme. Furthermore, the drug may cause false-negative results in allergy tests and can strengthen the effect of certain blood pressure-lowering agents and sympathomimetics. Patients should inform their healthcare provider of all concurrent treatments, including over-the-counter and herbal products.

Mechanism of Action

Central Suppression of Vestibular and Emetic Signaling

The primary mechanism involves Dimenhydrinate, which acts as a dual-target antagonist against Histamine H1 and Muscarinic Acetylcholine receptors concentrated in the brainstem. This dual blockade reduces nerve excitability within the vestibular nuclei and the Chemoreceptor Trigger Zone (CTZ) . By interrupting the signaling cascade from the inner ear to the central nervous system ( CNS), this mechanism results in vestibular pathway suppression and emetic reflex inhibition.


Supportive Microcirculatory and Neuronal Function

This domain encompasses the additional mechanistic actions of Nicotinic Acid and Pyridoxine. Nicotinic Acid acts on HCA2 receptors to trigger localized vasodilation, thereby increasing microcirculation to the inner ear structures. Simultaneously, Pyridoxine acts as a coenzyme essential for the metabolic function and synthesis of key inhibitory neurotransmitters in the CNS. This engagement of vascular and metabolic mechanisms contributes to the overall physiological modulation that occurs alongside the central suppressive effect.


Dual Modulation of CNS Activity

The overall physiological action is characterized by the interplay of two moieties within Dimenhydrinate: the component responsible for receptor antagonism induces CNS suppression, while the 8-Chlorotheophylline moiety acts as a weak Adenosine receptor antagonist. This mild CNS stimulant effect provides a counter-modulatory influence, modifying the degree of CNS depression associated with the central suppressive mechanism.

Dosage and Administration Information

How to Use Vertigo-Vomex: Administration Guidelines

Vertigo-Vomex, a combination product containing Dimenhydrinate, is administered via the oral route. Dosage is dependent on the specific formulation, which includes immediate-release tablets (e.g., 50 mg Dimenhydrinate) and sustained-release capsules.


Dosing and Administration Schedule

Instruction Domain Guidelines
Standard Adult Dose 50 mg to 100 mg of Dimenhydrinate per dose, with a maximum total daily intake generally not exceeding 400 mg for immediate-release forms.
Frequency Pattern Immediate-release forms are typically repeated every 4 to 6 hours as needed. Sustained-release capsules are often dosed once or twice daily, spaced by approximately 8 hours.
Prophylactic Timing For prevention of motion-induced symptoms, the initial dose should be taken 30 minutes to 1 hour prior to the start of the activity.

Procedural and Duration Constraints

The medicine is taken with liquid and can be administered independently of meals. Sustained-release capsules must be swallowed whole and not crushed or chewed to ensure the integrity of the controlled-release mechanism. Treatment is generally intended for short-term use for acute or situational symptoms, with continued use beyond two weeks requiring professional consultation.

Age-Group Guidance: Pediatric dosing is standardized on a lower, weight-adjusted basis. If a dose is missed, individuals should resume the schedule at the next prescribed time without taking a double dose to compensate. This structured protocol ensures the medicine is used within the established parameters.

Recent Clinical Evidence

Research evidence / Overview of studies for Vertigo-Vomex

Evidence for Acute Vertigo and Associated Nausea

Research exploring outcomes related to how symptoms change over time for acute vertigo episodes has utilized Randomized Controlled Trials (RCTs) that examined the antihistamine component, Dimenhydrinate, alone or in other fixed combinations. The studies examined populations with fluctuating or unstable symptoms in adults experiencing acute peripheral vertigo. The research monitored patient-reported outcomes describing perceived discomfort and markers of systemic or functional imbalance, such as the reported intensity of the spinning sensation and degree of associated nausea.

Findings describe patterns observed in these studies, which reported the evolution of symptoms during the study period, focusing on short-term symptom changes over defined time intervals. However, evidence is limited regarding the specific contribution of the Nicotinic Acid and Pyridoxine (Vitamin B6) components in this specific combination product. Current high-level research primarily examines the antihistamine component alone. Long-term effects are not fully established; follow-up durations were limited, meaning there is limited information for long-term outcomes.

Evidence for Motion Sickness Prevention

Research on motion sickness prevention has involved various controlled study types, including prophylactic trials and Systematic Reviews, to explore short-term symptom changes. These studies were conducted during periods of increased symptom activity. The research monitored outcomes capturing phases of heightened symptom activity, primarily monitoring the incidence of nausea and vomiting that may be experienced during travel or movement.

Key Uncertainties and Research Gaps

While the antihistamine component was studied for its intended uses, there is a lack of widely published, high-quality research that has specifically evaluated the clinical impact of combining Dimenhydrinate with Nicotinic Acid and Pyridoxine. Comparative evidence is lacking to definitively assess the contribution of the vitamin components. The evidence quality varies across studies, and long-term effects are not fully established.

Key Studies & References

  1. Dimenhydrinate: Drug Information (NIH MedlinePlus)
  2. Interventions for preventing motion sickness (Cochrane Review)

Frequently Asked Questions (FAQ)

Common questions about Vertigo-Vomex (FAQ)


Q: How quickly does Vertigo-Vomex start working for dizziness?

Official information regarding the active ingredient, Dimenhydrinate, indicates that for the prevention of symptoms, the initial dose is typically administered 30 minutes to 1 hour before exposure to motion or activity. This timing is based on when the drug is expected to be sufficiently absorbed and active in the body.


Q: Can Vertigo-Vomex be taken to prevent vertigo episodes?

Yes, the medication is indicated for the prevention and treatment of symptoms associated with motion sickness, which includes associated dizziness and nausea. The drug is often administered prophylactically (preventatively) before exposure to activities that typically trigger symptoms.


Q: What are the most common side effects people report with Vertigo-Vomex?

Regulatory documents list the most frequently reported adverse reactions as those related to Central Nervous System (CNS) depression and anticholinergic effects. The most common effects reported include drowsiness (somnolence) and symptoms such as dry mouth.


Q: Does Vertigo-Vomex interact with common pain relievers like ibuprofen?

Specific over-the-counter pain relievers like ibuprofen are not always listed individually in regulatory documents, but Vertigo-Vomex can cause additive effects when combined with any other medications that cause CNS depression (increased sleepiness) or have anticholinergic activity.


Q: Can taking Vertigo-Vomex affect my ability to drive?

Yes, official safety information cautions that activities requiring mental alertness, such as driving or operating machinery, may be affected due to the potential for drowsiness. This effect is related to the drug's properties as an antihistamine.


Q: Is it safe to take Vertigo-Vomex with blood pressure medication?

The active ingredient should be used with caution in patients with hypertension (high blood pressure). Official labeling notes that the drug may strengthen the effect of certain blood pressure-lowering agents. Concurrent use is generally evaluated by a healthcare provider due to the potential for interactions.


Q: What happens if I miss a scheduled dose of Vertigo-Vomex?

Regulatory instructions state that individuals should resume the schedule at the next prescribed time and not take a double dose to compensate for the missed one. The schedule should simply continue as originally intended.


Q: Can Vertigo-Vomex be given to children for travel sickness?

Yes, the active ingredient Dimenhydrinate is approved for use in children 2 years of age and older for the prevention and treatment of motion sickness. Pediatric use involves specific weight- or age-adjusted guidelines.


Q: Is Vertigo-Vomex safe for older adults to take?

Official regulatory guidance advises caution because older adults (65 years and older) may be more susceptible to the drug’s effects, including increased dizziness, confusion, and sedation. These effects are related to the drug's properties and how the body changes with age.


Q: Is there a maximum number of days or weeks I should take Vertigo-Vomex?

The drug is generally intended for short-term use for acute symptoms. Official instructions indicate that use beyond two weeks requires evaluation by a healthcare professional.


Q: Can long-term use of Vertigo-Vomex be harmful?

The drug is primarily intended for short-term use. Long-term effects are not fully established in available clinical data, and continued use beyond the recommended duration requires professional consultation.


Q: Is it possible to take Vertigo-Vomex with certain allergy medications?

Vertigo-Vomex contains an antihistamine, and combining it with other antihistamines or sedating allergy medications can cause additive sedation. This means there is a potential for intensified drowsiness and increased anticholinergic side effects.


Q: Are there special considerations for people with kidney or liver issues using Vertigo-Vomex?

Yes. Regulatory documents indicate that the drug is contraindicated (must not be used) in patients with severe hepatic (liver) or severe renal (kidney) impairment. For less severe impairment, caution is advised as the medication may accumulate in the body.


Q: Can Vertigo-Vomex cause confusion in older patients?

Yes, official safety information notes that older adults (65 years and older) may be more susceptible to CNS effects, including confusion, due to the drug's anticholinergic properties.


Q: Are there any documented drug interactions with herbal supplements and Vertigo-Vomex?

Official patient information advises that individuals should inform their healthcare provider about all concurrent treatments. This includes over-the-counter and herbal products, as there is a potential for unknown or documented interactions with the active ingredients.


Q: What is the standard frequency for taking Vertigo-Vomex?

For immediate-release forms of the active ingredient, Dimenhydrinate, the typical adult frequency is every 4 to 6 hours as needed for symptom relief.


Q: Can Vertigo-Vomex be taken at night to help with sleep?

The active ingredient in this medication is a sedating antihistamine that commonly causes drowsiness as a side effect. While the drug is not officially indicated as a sleep aid, this sedative effect is a recognized property of the medication.


Q: What class of drug does Vertigo-Vomex belong to?

Vertigo-Vomex is a combination product. It is primarily classified as an Antihistamine (First-Generation), an Antivertigo Agent, and an Antiemetic (anti-nausea drug) in regulatory documents.


Q: Is Vertigo-Vomex considered an anticholinergic drug?

Yes, the active antihistamine component, Dimenhydrinate, is known to have anticholinergic properties. This characteristic contributes to some of the side effects commonly reported, such as dry mouth.


Q: What are the ingredients besides the active one in Vertigo-Vomex tablets?

In addition to the active ingredients (Dimenhydrinate, Nicotinic Acid, and Pyridoxine), the tablets or capsules contain various inactive ingredients. These can include common excipients like microcrystalline cellulose, magnesium stearate, and other binding agents necessary for the product’s form.


Q: Do I need a prescription to buy Vertigo-Vomex?

In many jurisdictions, the active ingredient Dimenhydrinate is widely available as an Over-The-Counter (OTC) medication. It is approved for the temporary relief and prevention of motion sickness and associated symptoms.


Q: What should I do if I experience a rare but serious side effect from Vertigo-Vomex?

Official information states that if a serious adverse effect is suspected, immediate medical attention should be sought. Serious adverse effects may include symptoms like severe allergic reactions or a fast, pounding, or irregular heartbeat.


Q: Is it possible for Vertigo-Vomex to cause stomach upset?

Yes, official regulatory labeling lists gastrointestinal effects among the potential adverse reactions. These can include stomach discomfort, epigastric distress, and sometimes nausea or vomiting.


Q: Why is Vertigo-Vomex sometimes recommended for labyrinthitis?

The drug's active ingredient, Dimenhydrinate, works by suppressing signals in the inner ear's vestibular system, which is implicated in conditions like labyrinthitis. The drug is used for managing the related symptoms of dizziness, nausea, and vomiting.

How should Vertigo-Vomex be stored and disposed of?

How to Store and Dispose of Vertigo-Vomex

Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (typically 20 C to 25 C).
Protection Keep away from excessive heat, moisture, and light.
Packaging Keep the medicine in its original container, tightly closed.

Handling and Disposal

Regulatory documents emphasize that the medicine must be stored out of the sight and reach of children.

Do not store the product in the bathroom due to heat and humidity, and do not freeze it. For disposal, unused or expired medication must not be flushed down the toilet or poured into drains. Dispose of the product through an approved drug take-back program or according to specific local regulations for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vertigo-Vomex found in:

A-Z Index: